HOME >> MEDICINE >> NEWS
New therapeutic target identified in inherited brain tumor disorder

St. Louis, Nov. 1, 2005 -- Researchers studying a mouse model of neurofibromatosis 1 (NF1), a genetic condition that causes childhood brain tumors, have found their second new drug target in a year, a protein called methionine aminopeptidase-2 (MetAP2).

An established drug, fumagillin, is already known to suppress the activity of MetAP2. Researchers at Washington University School of Medicine in St. Louis showed that fumagillin significantly slowed the rapid proliferation of cultured mouse brain cells that resulted from the loss of Nf1, the gene that causes neurofibromatosis 1. Evaluation of the ability of this class of drugs to control brain tumor growth in small animal models is planned.

"This agent and others like it have already been in clinical trials as treatments for other tumors, so if we find that fumagillin inhibits brain tumor growth in preclinical studies, it will be a much smaller leap to using these compounds in patients with NF1," says senior investigator David H. Gutmann, M.D., Ph.D., the Donald O. Schnuck Family Professor of Neurology at Washington University School of Medicine in St. Louis and co-director of the neuro-oncology program at the Siteman Cancer Center.

Neurofibromatosis 1 affects more than 100,000 people in the United States and is one of the most common tumor predisposition syndromes. Gutmann and his colleagues discovered that abnormally high levels of MetAP2 may be a distinguishing characteristic of brain tumors in patients with NF1. Analyses of other similar brain tumors did not reveal the high MetAP2 levels characteristic of tumors caused by NF1.

To identify MetAP2, Gutmann collaborated with Jason D. Weber, Ph.D., assistant professor of medicine and of cellular biology and anatomy at the Washington University Neurofibromatosis Center. The center facilitates multidisciplinary neurofibromatosis research and is dedicated to developing better treatments to improve the lives of patients affected with neurofibromat
'"/>

Contact: Michael C. Purdy
purdym@wustl.edu
314-286-0122
Washington University School of Medicine
1-Nov-2005


Page: 1 2

Related medicine news :

1. Shark cartilage shows no benefit as a therapeutic agent for lung cancer
2. New therapeutic targets for neurodegenerative diseases
3. OCT1 required for therapeutic effects of diabetes drug Metformin
4. NeuroRx changes name to Neurotherapeutics
5. Olive Leaf report documents promising therapeutic interventions for 9-11 workers
6. T cells activated to fight HIV basis for dendritic cell therapeutic vaccine
7. Cerebrospinal fluid used to deliver therapeutics for Lou Gehrigs disease to brain
8. University to develop new therapeutics for cancer
9. Exubera: So far no evidence available of an additional therapeutic benefit
10. Nano-particles effective in killing cancer with one-two punch of chemotherapeutics
11. Researchers identify target for therapeutic drugs to fight most common adult brain cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/2/2020)... ... July 02, 2020 , ... ... dental offices for non-emergency work. In conjunction with the American Dental Association and ... dental practices in mid-May. , Due to safety concerns, the announcement sparked ...
(Date:7/1/2020)... ... July 01, 2020 , ... Psilera Bioscience ... psychedelics and analogues, announces its core executive team. The co-founders Drs. Jackie Salm ... novel formulations, and as distinguished researchers within the cannabis industry. They are joined ...
(Date:6/28/2020)... , ... June 26, 2020 , ... ... for participation in the revision and redesignation of the ANSI/APSP/ICC-7 2013 American National ... and Catch Basins. PHTA is seeking member participation on the PHTA-7 Standard Writing ...
(Date:6/28/2020)... ... June 26, 2020 , ... ... the Inland Empire’s premier residential addiction treatment center, proudly announces that it has ... includes special preparation for recovery in a world affected by Covid-19. , When ...
(Date:6/28/2020)... ... June 27, 2020 , ... The FSHD Society ... educational conference in the organization’s history. The online conference takes the place of ... was cancelled this year due to COVID-19. Nearly 300 individuals and families living ...
Breaking Medicine News(10 mins):
(Date:7/2/2020)... ... 2020 , ... AllenComm, the leader in transformative learning experiences , has ... compelling compliance training , onboarding , brand training , and ... expectations as a digital transformation partner for learning and development experts. , AllenComm ...
(Date:7/1/2020)... ... 2020 , ... Dexur’s analysis of medicare claims of hospitals within a 25-mile ... Southwest General Health Center , and Lutheran Hospital had the best ... value analysis tracks a patient’s episode of care from the date of admission for ...
(Date:6/28/2020)... ... 26, 2020 , ... Mediaplanet is proud to announce the ... providers, advocates, and scientists to spread awareness of chronic lung disease as well ... , More than 35 million Americans live with a chronic lung ...
Breaking Medicine Technology:
Cached News: